Abbott Laboratories $ABT Stock Holdings Lowered by New World Advisors LLC

New World Advisors LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 34.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,464 shares of the healthcare product maker’s stock after selling 1,799 shares during the period. New World Advisors LLC’s holdings in Abbott Laboratories were worth $471,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. IMG Wealth Management Inc. grew its holdings in shares of Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after acquiring an additional 167 shares during the last quarter. Elequin Capital LP acquired a new position in shares of Abbott Laboratories in the 1st quarter valued at $30,000. Anfield Capital Management LLC increased its stake in Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares in the last quarter. Vision Financial Markets LLC acquired a new stake in Abbott Laboratories during the 1st quarter worth about $33,000. Finally, Accent Capital Management LLC acquired a new position in shares of Abbott Laboratories in the first quarter worth about $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

ABT stock opened at $127.97 on Friday. The firm has a 50 day moving average of $129.95 and a two-hundred day moving average of $131.22. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a market capitalization of $222.52 billion, a price-to-earnings ratio of 16.04, a P/E/G ratio of 2.36 and a beta of 0.68. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The business had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. During the same quarter in the previous year, the business earned $1.21 EPS. Abbott Laboratories’s quarterly revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, November 17th. Investors of record on Wednesday, October 15th were issued a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date was Wednesday, October 15th. Abbott Laboratories’s payout ratio is 29.57%.

Analyst Ratings Changes

ABT has been the topic of a number of recent analyst reports. Evercore ISI cut their price target on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a report on Wednesday, October 15th. Weiss Ratings reissued a “buy (b)” rating on shares of Abbott Laboratories in a research note on Wednesday, October 8th. Daiwa Capital Markets raised their target price on Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. The Goldman Sachs Group upped their price target on Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Finally, Sanford C. Bernstein increased their price objective on Abbott Laboratories from $145.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $147.00.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.